Daniela Lenggenhager
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Daniela Lenggenhager has a total of 211 co-authors. Here are the top co-authors by number of shared publications:
- Achim Weber
University of Zurich Zurich Switzerland
6 shared publications - Anne-Laure Leblond
Department of Pathology and Molecular Pathology University of Zurich (UZH) and University Hospital Zurich (USZ) Zurich Switzerland
3 shared publications Birgit Helmchen
Department of Pathology and Molecular Pathology, University of Zurich (UZH) and University Hospital Zurich (USZ), Zurich, Switzerland
2 shared publications- Enni Markkanen
Institute of Veterinary Pharmacology and Toxicology, Vetsuisse Faculty, University of Zurich, 8057 Zurich, Switzerland
2 shared publications - Fritjof Helmchen
Brain Research Institute, University of Zürich, Zürich, Switzerland
2 shared publications - Harald Seeger
Department of Nephrology, Kantonsspital Baden, 5404 Baden, Switzerland
2 shared publications
Latest Publications
- Open Access
- 3 November 2026
- Published by Wiley in Cancer Medicine
- Vol. 15 (11)
Upfront Comprehensive Genomic Profiling in Advanced Biliary Tract Cancer: Real‐World Implementation and Clinical Outcomes
Background: Biliary Tract Cancers (BTCs) are difficult‐to‐treat malignancies with limited therapeutic options and dismal prognosis. Upfront comprehensive genomic profiling (CGP) is recommended for advanced BTC to identify actionable alterations, but its real‐world implementation remains underexplored. Methods: In 2019, we implemented upfront CGP for advanced BTC at our institution. Molecular profiling results were reviewed within our institutional molecular tumor board when clinically applicable. Patients were followed throughout their disease course. Results: A total of 80 patients with locally unresectable ( n = 14) or metastatic ( n = 66) BTC underwent CGP. Testing was performed on cytology material (6/80), tumor biopsies (38/80), or surgical specimens (36/80). In 59/80 cases (73.8%) testing was carried out prior to the beginning of palliative first‐line treatment. In 42/80 (52.5%) cases, at least one clinically actionable genomic alteration was identified. The most frequent actionable alterations involved IDH1 (13.8%), FGFR2 (8.8%), ERBB2 (HER2) (5.0%), KRAS G12C (2.5%), and BRAF (1.3%). Alterations in DNA damage response genes were detected in 11/80 tumors, and 3/80 were dMMR/MSI‐H. FGFR2 and IDH1 mutations were detected in ICC only, while HER2 alterations were more commonly detected in ECC and GBC. 11/42 patients with a clinically actionable alteration received targeted treatment during the disease course (1 first‐line, 10 later lines). Among patients with an evaluable preceding systemic treatment line, treatment duration was longer with molecularly matched treatment than with the immediately preceding treatment line ( p = 0.0391). 2/14 patients with initially unresectable BTC achieved secondary resectability during molecularly matched treatment. Conclusion: Upfront CGP is feasible in routine clinical practice and identifies clinically actionable alterations in a substantial proportion of patients with advanced BTC. However, only a subset received molecularly matched treatment, highlighting a gap between molecular actionability and treatment implementation. Timely access to matched therapies remains critical to the clinical utility of precision oncology in BTC.
- 3 November 2026
- Published by Wiley in Cancer Medicine
- Vol. 15 (11)
Open AccessUpfront Comprehensive Genomic Profiling in Advanced Biliary Tract Cancer: Real‐World Implementation and Clinical Outcomes
Background: Biliary Tract Cancers (BTCs) are difficult‐to‐treat malignancies with limited therapeutic options and dismal prognosis. Upfront comprehensive genomic profiling (CGP) is recommended for advanced BTC to identify actionable alterations, but its real‐world implementation remains underexplored. Methods: In 2019, we implemented upfront CGP for advanced BTC at our institution. Molecular profiling results were reviewed within our institutional molecular tumor board when clinically applicable. Patients were followed throughout their disease course. Results: A total of 80 patients with locally unresectable ( n = 14) or metastatic ( n = 66) BTC underwent CGP. Testing was performed on cytology material (6/80), tumor biopsies (38/80), or surgical specimens (36/80). In 59/80 cases (73.8%) testing was carried out prior to the beginning of palliative first‐line treatment. In 42/80 (52.5%) cases, at least one clinically actionable genomic alteration was identified. The most frequent actionable alterations involved IDH1 (13.8%), FGFR2 (8.8%), ERBB2 (HER2) (5.0%), KRAS G12C (2.5%), and BRAF (1.3%). Alterations in DNA damage response genes were detected in 11/80 tumors, and 3/80 were dMMR/MSI‐H. FGFR2 and IDH1 mutations were detected in ICC only, while HER2 alterations were more commonly detected in ECC and GBC. 11/42 patients with a clinically actionable alteration received targeted treatment during the disease course (1 first‐line, 10 later lines). Among patients with an evaluable preceding systemic treatment line, treatment duration was longer with molecularly matched treatment than with the immediately preceding treatment line ( p = 0.0391). 2/14 patients with initially unresectable BTC achieved secondary resectability during molecularly matched treatment. Conclusion: Upfront CGP is feasible in routine clinical practice and identifies clinically actionable alterations in a substantial proportion of patients with advanced BTC. However, only a subset received molecularly matched treatment, highlighting a gap between molecular actionability and treatment implementation. Timely access to matched therapies remains critical to the clinical utility of precision oncology in BTC.
- Open Access
- 27 October 2026
- Published by Wiley in Histopathology
Lipidic obstruction of sinusoids ( LOS ): a potentially serious complication of steatotic liver disease
Introduction: During routine examination of specimens from patients with steatotic liver disease (SLD), we repeatedly observed a peculiar phenomenon characterized by obstruction of the hepatic sinusoids by lipid vacuoles (lipidic obstruction of sinusoids, LOS). These changes were reminiscent of pseudopeliotic steatosis (PPS), a complication following liver transplantation (LT), but notably occurred outside this context. The aim of our study was to identify diagnostic indicators for LOS and to determine its clinical significance. Methods: Liver specimens routinely sent to our institute between 2019 and 2024 with SLD were examined for LOS. The extracellular nature of the fat and the compression of the sinusoids were demonstrated by ancillary stains (Gomori, CD68, collagen IV). The extent of the LOS was quantified by measuring the area and maximum diameter of fat lakes. The clinical course of patients with LOS was retrospectively evaluated and correlated with the histological findings. Results: LOS was observed in eight patients, ranging from focal to very extensive extracellular fat. The diagnosis was based on routine histology, supplemented by collagen IV stain highlighting double contours of sinusoids. The morphological findings suggested that lipidic obstruction of the hepatic sinusoids was a key pathophysiological factor. LOS was associated with liver necrosis and activation of macrophages. Patients with LOS exhibited a variable clinical course, ranging from subclinical to severe, including LT or even death. The extent of fat lakes correlated with the severity of the clinical course. Conclusions: We suggest the term LOS for a particular pattern of liver damage that can occur in SLD outside the transplantation setting and may lead to impaired hepatic blood flow. LOS is associated with a variable clinical presentation, ranging from subclinical to fatal. Clinicians and pathologists should be aware of this complication of SLD, which is diagnosed by liver histology.
- 27 October 2026
- Published by Wiley in Histopathology
Open AccessLipidic obstruction of sinusoids ( LOS ): a potentially serious complication of steatotic liver disease
Introduction: During routine examination of specimens from patients with steatotic liver disease (SLD), we repeatedly observed a peculiar phenomenon characterized by obstruction of the hepatic sinusoids by lipid vacuoles (lipidic obstruction of sinusoids, LOS). These changes were reminiscent of pseudopeliotic steatosis (PPS), a complication following liver transplantation (LT), but notably occurred outside this context. The aim of our study was to identify diagnostic indicators for LOS and to determine its clinical significance. Methods: Liver specimens routinely sent to our institute between 2019 and 2024 with SLD were examined for LOS. The extracellular nature of the fat and the compression of the sinusoids were demonstrated by ancillary stains (Gomori, CD68, collagen IV). The extent of the LOS was quantified by measuring the area and maximum diameter of fat lakes. The clinical course of patients with LOS was retrospectively evaluated and correlated with the histological findings. Results: LOS was observed in eight patients, ranging from focal to very extensive extracellular fat. The diagnosis was based on routine histology, supplemented by collagen IV stain highlighting double contours of sinusoids. The morphological findings suggested that lipidic obstruction of the hepatic sinusoids was a key pathophysiological factor. LOS was associated with liver necrosis and activation of macrophages. Patients with LOS exhibited a variable clinical course, ranging from subclinical to severe, including LT or even death. The extent of fat lakes correlated with the severity of the clinical course. Conclusions: We suggest the term LOS for a particular pattern of liver damage that can occur in SLD outside the transplantation setting and may lead to impaired hepatic blood flow. LOS is associated with a variable clinical presentation, ranging from subclinical to fatal. Clinicians and pathologists should be aware of this complication of SLD, which is diagnosed by liver histology.
- Open Access
- 14 October 2024
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-12
HEV ORF2 protein-antibody complex deposits are associated with glomerulonephritis in hepatitis E with reduced immune status
Hepatitis E virus (HEV) infection, one of the most common forms of hepatitis worldwide, is often associated with extrahepatic, particularly renal, manifestations. However, the underlying mechanisms are incompletely understood. Here, we report the development of a de novo immune complex-mediated glomerulonephritis (GN) in a kidney transplant recipient with chronic hepatitis E. Applying immunostaining, electron microscopy, and mass spectrometry after laser-capture microdissection, we show that GN develops in parallel with increasing glomerular deposition of a non-infectious, genome-free and non-glycosylated HEV open reading frame 2 (ORF2) capsid protein. No productive HEV infection of kidney cells is detected. Patients with acute hepatitis E display similar but less pronounced deposits. Our results establish a link between the production of HEV ORF2 protein and the development of hepatitis E-associated GN in the immunocompromised state. The formation of glomerular IgG-HEV ORF2 immune complexes discovered here provides a potential mechanistic explanation of how the hepatotropic HEV can cause variable renal manifestations. These findings directly provide a tool for etiology-based diagnosis of hepatitis E-associated GN as a distinct entity and suggest therapeutic implications.
- 14 October 2024
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-12
Open AccessHEV ORF2 protein-antibody complex deposits are associated with glomerulonephritis in hepatitis E with reduced immune status
Hepatitis E virus (HEV) infection, one of the most common forms of hepatitis worldwide, is often associated with extrahepatic, particularly renal, manifestations. However, the underlying mechanisms are incompletely understood. Here, we report the development of a de novo immune complex-mediated glomerulonephritis (GN) in a kidney transplant recipient with chronic hepatitis E. Applying immunostaining, electron microscopy, and mass spectrometry after laser-capture microdissection, we show that GN develops in parallel with increasing glomerular deposition of a non-infectious, genome-free and non-glycosylated HEV open reading frame 2 (ORF2) capsid protein. No productive HEV infection of kidney cells is detected. Patients with acute hepatitis E display similar but less pronounced deposits. Our results establish a link between the production of HEV ORF2 protein and the development of hepatitis E-associated GN in the immunocompromised state. The formation of glomerular IgG-HEV ORF2 immune complexes discovered here provides a potential mechanistic explanation of how the hepatotropic HEV can cause variable renal manifestations. These findings directly provide a tool for etiology-based diagnosis of hepatitis E-associated GN as a distinct entity and suggest therapeutic implications.
- Open Access
- 2 October 2024
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-21
Molecular and functional landscape of malignant serous effusions for precision oncology
Personalized treatment for patients with advanced solid tumors critically depends on the deep characterization of tumor cells from patient biopsies. Here, we comprehensively characterize a pan-cancer cohort of 150 malignant serous effusion (MSE) samples at the cellular, molecular, and functional level. We find that MSE-derived cancer cells retain the genomic and transcriptomic profiles of their corresponding primary tumors, validating their use as a patient-relevant model system for solid tumor biology. Integrative analyses reveal that baseline gene expression patterns relate to global ex vivo drug sensitivity, while high-throughput drug-induced transcriptional changes in MSE samples are indicative of drug mode of action and acquired treatment resistance. A case study exemplifies the added value of multi-modal MSE profiling for patients who lack genetically stratified treatment options. In summary, our study provides a functional multi-omics view on a pan-cancer solid tumor cohort and underlines the feasibility and utility of MSE-based precision oncology.
- 2 October 2024
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-21
Open AccessMolecular and functional landscape of malignant serous effusions for precision oncology
Personalized treatment for patients with advanced solid tumors critically depends on the deep characterization of tumor cells from patient biopsies. Here, we comprehensively characterize a pan-cancer cohort of 150 malignant serous effusion (MSE) samples at the cellular, molecular, and functional level. We find that MSE-derived cancer cells retain the genomic and transcriptomic profiles of their corresponding primary tumors, validating their use as a patient-relevant model system for solid tumor biology. Integrative analyses reveal that baseline gene expression patterns relate to global ex vivo drug sensitivity, while high-throughput drug-induced transcriptional changes in MSE samples are indicative of drug mode of action and acquired treatment resistance. A case study exemplifies the added value of multi-modal MSE profiling for patients who lack genetically stratified treatment options. In summary, our study provides a functional multi-omics view on a pan-cancer solid tumor cohort and underlines the feasibility and utility of MSE-based precision oncology.
- Open Access
- 4 April 2024
- Published by Wiley in Histopathology
- Vol. 85 (1) , 171-181
Identification of tumour regression in neoadjuvantly treated pancreatic cancer is based on divergent and nonspecific criteria
Aims: Following the increased use of neoadjuvant therapy for pancreatic cancer, grading of tumour regression (TR) has become part of routine diagnostics. However, it suffers from marked interobserver variation, which is mainly ascribed to the subjectivity of the defining criteria of the categories in TR grading systems. We hypothesized that a further cause for the interobserver variation is the use of divergent and nonspecific morphological criteria to identify tumour regression.Methods and Results: Twenty treatment‐naïve pancreatic cancers and 20 pancreatic cancers treated with neoadjuvant chemotherapy were reviewed by three experienced pancreatic pathologists who, blinded for treatment status, categorized each tumour as treatment‐naïve or neoadjuvantly treated, and annotated all tissue areas they considered showing tumour regression. Only 50%–65% of the cases were categorized correctly, and the annotated tissue areas were highly discrepant (only 3%–41% overlap). When the prevalence of various morphological features deemed to indicate TR was compared between treatment‐naïve and neoadjuvantly treated tumours, only one pattern, characterized by reduced cancer cell density and prominent stroma affecting a large area of the tumour bed, occurred significantly more frequently, but not exclusively, in the neoadjuvantly treated group. Finally, stromal features, both morphological and biological, were investigated as possible markers for tumour regression, but failed to distinguish TR from native tumour stroma.Conclusion: There is considerable divergence in opinion between pathologists when it comes to the identification of tumour regression. Reliable identification of TR is only possible if it is extensive, while lesser degrees of treatment effect cannot be recognized with certainty.
- 4 April 2024
- Published by Wiley in Histopathology
- Vol. 85 (1) , 171-181
Open AccessIdentification of tumour regression in neoadjuvantly treated pancreatic cancer is based on divergent and nonspecific criteria
Aims: Following the increased use of neoadjuvant therapy for pancreatic cancer, grading of tumour regression (TR) has become part of routine diagnostics. However, it suffers from marked interobserver variation, which is mainly ascribed to the subjectivity of the defining criteria of the categories in TR grading systems. We hypothesized that a further cause for the interobserver variation is the use of divergent and nonspecific morphological criteria to identify tumour regression.Methods and Results: Twenty treatment‐naïve pancreatic cancers and 20 pancreatic cancers treated with neoadjuvant chemotherapy were reviewed by three experienced pancreatic pathologists who, blinded for treatment status, categorized each tumour as treatment‐naïve or neoadjuvantly treated, and annotated all tissue areas they considered showing tumour regression. Only 50%–65% of the cases were categorized correctly, and the annotated tissue areas were highly discrepant (only 3%–41% overlap). When the prevalence of various morphological features deemed to indicate TR was compared between treatment‐naïve and neoadjuvantly treated tumours, only one pattern, characterized by reduced cancer cell density and prominent stroma affecting a large area of the tumour bed, occurred significantly more frequently, but not exclusively, in the neoadjuvantly treated group. Finally, stromal features, both morphological and biological, were investigated as possible markers for tumour regression, but failed to distinguish TR from native tumour stroma.Conclusion: There is considerable divergence in opinion between pathologists when it comes to the identification of tumour regression. Reliable identification of TR is only possible if it is extensive, while lesser degrees of treatment effect cannot be recognized with certainty.
- Open Access
A HEV ORF2 protein-mediated mechanism of hepatitis E-associated kidney disease
Hepatitis E virus (HEV) infection, one of the most common forms of hepatitis worldwide, is often associated with extrahepatic, particularly renal, manifestations. However, the underlying mechanisms are incompletely understood. Here, we report the development of a de novo immune complex-mediated glomerulonephritis (GN) in a kidney transplant recipient with chronic hepatitis E. Applying immunostaining, electron microscopy, and mass spectrometry after laser-capture microdissection, we show that GN developed in parallel with increasing glomerular deposition of a noninfectious form of HEV open reading frame 2 (ORF2, capsid) protein secreted in excess. HEV particles or RNA, however, were not detectable. Patients with acute hepatitis E displayed similar but less pronounced deposits. Our results elucidate an immunologic mechanism by which this hepatotropic virus causes variable renal manifestations and establish a link between the HEV ORF2 protein and hepatitis E-associated GN. They directly provide a tool for etiology-based diagnosis of HEV-associated GN as a distinct entity and suggest therapeutic implications.
Open AccessA HEV ORF2 protein-mediated mechanism of hepatitis E-associated kidney disease
Hepatitis E virus (HEV) infection, one of the most common forms of hepatitis worldwide, is often associated with extrahepatic, particularly renal, manifestations. However, the underlying mechanisms are incompletely understood. Here, we report the development of a de novo immune complex-mediated glomerulonephritis (GN) in a kidney transplant recipient with chronic hepatitis E. Applying immunostaining, electron microscopy, and mass spectrometry after laser-capture microdissection, we show that GN developed in parallel with increasing glomerular deposition of a noninfectious form of HEV open reading frame 2 (ORF2, capsid) protein secreted in excess. HEV particles or RNA, however, were not detectable. Patients with acute hepatitis E displayed similar but less pronounced deposits. Our results elucidate an immunologic mechanism by which this hepatotropic virus causes variable renal manifestations and establish a link between the HEV ORF2 protein and hepatitis E-associated GN. They directly provide a tool for etiology-based diagnosis of HEV-associated GN as a distinct entity and suggest therapeutic implications.
- Open Access
- 8 March 2023
- Published by S. Karger AG in Acta Cytologica
- Vol. 67 (4) , 444-450
Utility of BAP1, p16, and Methylthio-Adenosine Phosphorylase Immunohistochemistry in Cytological and Histological Samples of Pleural Mesotheliomas
Introduction: In most cases, the diagnostic workup of pleural mesotheliomas (MPMs) starts with cytological examination of pleural effusion, but histology is needed to confirm the diagnosis. The introduction of BAP1 and methylthio-adenosine phosphorylase (MTAP) immunohistochemistry has become a powerful tool to confirm the malignant nature of mesothelial proliferations also in cytological specimens. The objective of this study was to determine the concordance of BAP1, MTAP, and p16 expression between cytological and histological samples of patients with MPM. Methods: Immunohistochemistry of BAP1, MTAP, and p16 was performed on cytological samples and compared with the corresponding histological specimen of 25 patients with MPM. Inflammatory and stromal cells served as positive internal control for all three markers. In addition, samples of 11 patients with reactive mesothelial proliferations served as an external control group. Results: Loss of BAP1, MTAP, and p16 expression was found in 68%, 72%, and 92% of MPM, respectively. Loss of MTAP was associated with loss of p16 expression in all cases. Concordance of BAP1 between cytological and corresponding histological samples was 100% (kappa coefficient 1; p = 0.008). For MTAP and p16, kappa coefficient was 0.9 (p = 0.01) and 0.8 (p = 0.7788), respectively. Conclusions: Concordant BAP1, MTAP, and p16 expression is found between cytological and corresponding histological samples, indicating that a reliable diagnosis of MPM can be made on cytology only. Of the three markers, BAP1 and MTAP are most reliable in distinguishing malignant from reactive mesothelial proliferations.
- 8 March 2023
- Published by S. Karger AG in Acta Cytologica
- Vol. 67 (4) , 444-450
Open AccessUtility of BAP1, p16, and Methylthio-Adenosine Phosphorylase Immunohistochemistry in Cytological and Histological Samples of Pleural Mesotheliomas
Introduction: In most cases, the diagnostic workup of pleural mesotheliomas (MPMs) starts with cytological examination of pleural effusion, but histology is needed to confirm the diagnosis. The introduction of BAP1 and methylthio-adenosine phosphorylase (MTAP) immunohistochemistry has become a powerful tool to confirm the malignant nature of mesothelial proliferations also in cytological specimens. The objective of this study was to determine the concordance of BAP1, MTAP, and p16 expression between cytological and histological samples of patients with MPM. Methods: Immunohistochemistry of BAP1, MTAP, and p16 was performed on cytological samples and compared with the corresponding histological specimen of 25 patients with MPM. Inflammatory and stromal cells served as positive internal control for all three markers. In addition, samples of 11 patients with reactive mesothelial proliferations served as an external control group. Results: Loss of BAP1, MTAP, and p16 expression was found in 68%, 72%, and 92% of MPM, respectively. Loss of MTAP was associated with loss of p16 expression in all cases. Concordance of BAP1 between cytological and corresponding histological samples was 100% (kappa coefficient 1; p = 0.008). For MTAP and p16, kappa coefficient was 0.9 (p = 0.01) and 0.8 (p = 0.7788), respectively. Conclusions: Concordant BAP1, MTAP, and p16 expression is found between cytological and corresponding histological samples, indicating that a reliable diagnosis of MPM can be made on cytology only. Of the three markers, BAP1 and MTAP are most reliable in distinguishing malignant from reactive mesothelial proliferations.
- Open Access
- 28 October 2022
- Published by Wiley in Histopathology
- Vol. 82 (2) , 354-358
Immunohistochemistry for hepatitis E virus capsid protein cross‐reacts with cytomegalovirus‐infected cells: a potential diagnostic pitfall
Immunohistochemistry for hepatitis E virus (HEV) ORF2 (capsid) protein is a powerful tool for tissue-based diagnosis of hepatitis E, particularly useful in evaluating abnormal liver values in immunocompromised patients. We report here a previously unobserved reactivity of the HEV ORF2 antibody to human cytomegalovirus (CMV) proteins and contrast the staining patterns encountered in HEV and CMV infection, respectively. As part of a routine diagnostic work-up, the liver biopsy of an immunocompromised patient with elevated liver values was examined histologically for infection with viruses including CMV and HEV. Cytopathic changes were found, suggestive of CMV infection, which was confirmed by immunohistochemistry. Surprisingly, reactivity of a portion of CMV-infected cells with a mouse monoclonal antibody (clone 1E6) against HEV ORF2 protein was also detected. This observation prompted a screening of 22 further specimens (including liver, gastrointestinal, lung, brain and placental biopsies) with confirmed CMV infection/reactivation. Immunoreactivity of CMV-infected cells with HEV ORF2 antibody was observed in 18 of 23 specimens. While the HEV ORF2 antibody showed cytoplasmic, nuclear and canalicular positivity in hepatitis E cases, positivity in CMV-infected cells was limited to the nucleus. In conclusion, the HEV ORF2 antibody (clone 1E6) shows unexpected immunoreactivity against CMV proteins. In contrast to the hepatitis E staining pattern with cytoplasmic, nuclear and occasional canalicular positivity, reactivity in CMV-infected cells is restricted to the nucleus. Awareness of this cross-reactivity and knowledge of the differences in staining patterns will prevent pathologists from misinterpreting positive HEV ORF2 immunohistochemistry in liver specimens.
- 28 October 2022
- Published by Wiley in Histopathology
- Vol. 82 (2) , 354-358
Open AccessImmunohistochemistry for hepatitis E virus capsid protein cross‐reacts with cytomegalovirus‐infected cells: a potential diagnostic pitfall
Immunohistochemistry for hepatitis E virus (HEV) ORF2 (capsid) protein is a powerful tool for tissue-based diagnosis of hepatitis E, particularly useful in evaluating abnormal liver values in immunocompromised patients. We report here a previously unobserved reactivity of the HEV ORF2 antibody to human cytomegalovirus (CMV) proteins and contrast the staining patterns encountered in HEV and CMV infection, respectively. As part of a routine diagnostic work-up, the liver biopsy of an immunocompromised patient with elevated liver values was examined histologically for infection with viruses including CMV and HEV. Cytopathic changes were found, suggestive of CMV infection, which was confirmed by immunohistochemistry. Surprisingly, reactivity of a portion of CMV-infected cells with a mouse monoclonal antibody (clone 1E6) against HEV ORF2 protein was also detected. This observation prompted a screening of 22 further specimens (including liver, gastrointestinal, lung, brain and placental biopsies) with confirmed CMV infection/reactivation. Immunoreactivity of CMV-infected cells with HEV ORF2 antibody was observed in 18 of 23 specimens. While the HEV ORF2 antibody showed cytoplasmic, nuclear and canalicular positivity in hepatitis E cases, positivity in CMV-infected cells was limited to the nucleus. In conclusion, the HEV ORF2 antibody (clone 1E6) shows unexpected immunoreactivity against CMV proteins. In contrast to the hepatitis E staining pattern with cytoplasmic, nuclear and occasional canalicular positivity, reactivity in CMV-infected cells is restricted to the nucleus. Awareness of this cross-reactivity and knowledge of the differences in staining patterns will prevent pathologists from misinterpreting positive HEV ORF2 immunohistochemistry in liver specimens.
- Open Access
- 26 January 2022
- Published by Springer Nature in Oncogene
- Vol. 41 (10) , 1507-1517
De novo expression of gastrokines in pancreatic precursor lesions impede the development of pancreatic cancer
Molecular events occurring in stepwise progression from pre-malignant lesions (pancreatic intraepithelial neoplasia; PanIN) to the development of pancreatic ductal adenocarcinoma (PDAC) are poorly understood. Thus, characterization of early PanIN lesions may reveal markers that can help in diagnosing PDAC at an early stage and allow understanding the pathology of the disease. We performed the molecular and histological assessment of patient-derived PanINs, tumor tissues and pancreas from mouse models with PDAC (KC mice that harbor K-RAS mutation in pancreatic tissue), where we noted marked upregulation of gastrokine (GKN) proteins. To further understand the role of gastrokine proteins in PDAC development, GKN-deficient KC mice were developed by intercrossing gastrokine-deficient mice with KC mice. Panc-02 (pancreatic cancer cells of mouse origin) were genetically modified to express GKN1 for further in vitro and in vivo analysis. Our results show that gastrokine proteins were absent in healthy pancreas and invasive cancer, while its expression was prominent in low-grade PanINs. We could detect these proteins in pancreatic juice and serum of KC mice. Furthermore, accelerated PanIN and tumor development were noted in gastrokine deficient KC mice. Loss of gastrokine 1 protein delayed apoptosis during carcinogenesis leading to the development of desmoplastic stroma while loss of gastrokine 2 increased the proliferation rate in precursor lesions. In summary, we identified gastrokine proteins in early pancreatic precursor lesions, where gastrokine proteins delay pancreatic carcinogenesis.
- 26 January 2022
- Published by Springer Nature in Oncogene
- Vol. 41 (10) , 1507-1517
Open AccessDe novo expression of gastrokines in pancreatic precursor lesions impede the development of pancreatic cancer
Molecular events occurring in stepwise progression from pre-malignant lesions (pancreatic intraepithelial neoplasia; PanIN) to the development of pancreatic ductal adenocarcinoma (PDAC) are poorly understood. Thus, characterization of early PanIN lesions may reveal markers that can help in diagnosing PDAC at an early stage and allow understanding the pathology of the disease. We performed the molecular and histological assessment of patient-derived PanINs, tumor tissues and pancreas from mouse models with PDAC (KC mice that harbor K-RAS mutation in pancreatic tissue), where we noted marked upregulation of gastrokine (GKN) proteins. To further understand the role of gastrokine proteins in PDAC development, GKN-deficient KC mice were developed by intercrossing gastrokine-deficient mice with KC mice. Panc-02 (pancreatic cancer cells of mouse origin) were genetically modified to express GKN1 for further in vitro and in vivo analysis. Our results show that gastrokine proteins were absent in healthy pancreas and invasive cancer, while its expression was prominent in low-grade PanINs. We could detect these proteins in pancreatic juice and serum of KC mice. Furthermore, accelerated PanIN and tumor development were noted in gastrokine deficient KC mice. Loss of gastrokine 1 protein delayed apoptosis during carcinogenesis leading to the development of desmoplastic stroma while loss of gastrokine 2 increased the proliferation rate in precursor lesions. In summary, we identified gastrokine proteins in early pancreatic precursor lesions, where gastrokine proteins delay pancreatic carcinogenesis.
- Top Cited PapersOpen Access
- 24 March 2021
- Published by Springer Nature in Nature
- Vol. 592 (7854) , 450-456
NASH limits anti-tumour surveillance in immunotherapy-treated HCC
Hepatocellular carcinoma (HCC) can have viral or non-viral causes1–5. Non-alcoholic steatohepatitis (NASH) is an important driver of HCC. Immunotherapy has been approved for treating HCC, but biomarker-based stratification of patients for optimal response to therapy is an unmet need6,7. Here we report the progressive accumulation of exhausted, unconventionally activated CD8+PD1+T cells in NASH-affected livers. In preclinical models of NASH-induced HCC, therapeutic immunotherapy targeted at programmed death-1 (PD1) expanded activated CD8+PD1+T cells within tumours but did not lead to tumour regression, which indicates that tumour immune surveillance was impaired. When given prophylactically, anti-PD1 treatment led to an increase in the incidence of NASH–HCC and in the number and size of tumour nodules, which correlated with increased hepatic CD8+PD1+CXCR6+, TOX+, and TNF+T cells. The increase in HCC triggered by anti-PD1 treatment was prevented by depletion of CD8+T cells or TNF neutralization, suggesting that CD8+T cells help to induce NASH–HCC, rather than invigorating or executing immune surveillance. We found similar phenotypic and functional profiles in hepatic CD8+PD1+T cells from humans with NAFLD or NASH. A meta-analysis of three randomized phase III clinical trials that tested inhibitors of PDL1 (programmed death-ligand 1) or PD1 in more than 1,600 patients with advanced HCC revealed that immune therapy did not improve survival in patients with non-viral HCC. In two additional cohorts, patients with NASH-driven HCC who received anti-PD1 or anti-PDL1 treatment showed reduced overall survival compared to patients with other aetiologies. Collectively, these data show that non-viral HCC, and particularly NASH–HCC, might be less responsive to immunotherapy, probably owing to NASH-related aberrant T cell activation causing tissue damage that leads to impaired immune surveillance. Our data provide a rationale for stratification of patients with HCC according to underlying aetiology in studies of immunotherapy as a primary or adjuvant treatment.
- 24 March 2021
- Published by Springer Nature in Nature
- Vol. 592 (7854) , 450-456
Top Cited PapersOpen AccessNASH limits anti-tumour surveillance in immunotherapy-treated HCC
Hepatocellular carcinoma (HCC) can have viral or non-viral causes1–5. Non-alcoholic steatohepatitis (NASH) is an important driver of HCC. Immunotherapy has been approved for treating HCC, but biomarker-based stratification of patients for optimal response to therapy is an unmet need6,7. Here we report the progressive accumulation of exhausted, unconventionally activated CD8+PD1+T cells in NASH-affected livers. In preclinical models of NASH-induced HCC, therapeutic immunotherapy targeted at programmed death-1 (PD1) expanded activated CD8+PD1+T cells within tumours but did not lead to tumour regression, which indicates that tumour immune surveillance was impaired. When given prophylactically, anti-PD1 treatment led to an increase in the incidence of NASH–HCC and in the number and size of tumour nodules, which correlated with increased hepatic CD8+PD1+CXCR6+, TOX+, and TNF+T cells. The increase in HCC triggered by anti-PD1 treatment was prevented by depletion of CD8+T cells or TNF neutralization, suggesting that CD8+T cells help to induce NASH–HCC, rather than invigorating or executing immune surveillance. We found similar phenotypic and functional profiles in hepatic CD8+PD1+T cells from humans with NAFLD or NASH. A meta-analysis of three randomized phase III clinical trials that tested inhibitors of PDL1 (programmed death-ligand 1) or PD1 in more than 1,600 patients with advanced HCC revealed that immune therapy did not improve survival in patients with non-viral HCC. In two additional cohorts, patients with NASH-driven HCC who received anti-PD1 or anti-PDL1 treatment showed reduced overall survival compared to patients with other aetiologies. Collectively, these data show that non-viral HCC, and particularly NASH–HCC, might be less responsive to immunotherapy, probably owing to NASH-related aberrant T cell activation causing tissue damage that leads to impaired immune surveillance. Our data provide a rationale for stratification of patients with HCC according to underlying aetiology in studies of immunotherapy as a primary or adjuvant treatment.